Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 9Withdrawn 2Terminated 2Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 4Breast Neoplasms 4Sarcoma 3Stomach Neoplasms 2Dendritic Cell Sarcoma, Interdigitating 2Wilms Tumor 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Mediastinal Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1Advanced Gastric Cancer 1

Interventions

polatuzumab vedotin 2glofitamab 2Prednisone 2Doxorubicin 2Cyclophosphamide 2relmacabtagene autoleucel 1obinutuzumab 1axicabtagene ciloleucel 1Rituximab 1Oxaliplatin 1Gemcitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Dendritic Cell Sarcoma, Interdigitating × Doxorubicin × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡